An interventional study of Ready-to-eat wholegrain porridge in Gestational Diabetes, Glucose Tolerance Impaired in Pregnancy and Glucose Tolerance Impaired, sponsored by Stoffwechselzentrum Rhein - Pfalz. Withdrawn at 1 site in Germany. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Treatment
Recruitment was not possible.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Diabetes, Gestational with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Germany.
Among the 13 studies in Diabetes, Gestational with a site in Germany, this one is one of 2 that started in 2023, is one of 6 with no phase, and was the 8th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →6 of the 13 studies in Diabetes, Gestational with a site in Germany are open now. Recruiting first, the newest first:
Bionime Corporation · Sites in Germany
Ages 18+ · Women only
University of Ulm · Sites in Germany
Ages 18+ · Healthy volunteers
Jena University Hospital · Sites in Germany
Ages 18+ · Women only
Charite University, Berlin, Germany · Sites in Germany
Ages 18–45 · Women only · Healthy volunteers
University Hospital Tuebingen · Sites in Germany
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 7 interventional studies, 450 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 9 most frequent:
Stoffwechselzentrum Rhein - Pfalz is the lead sponsor of 3 studies on the registry; none are open to participants now.
Stoffwechselzentrum Rhein - Pfalz has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes, Gestational with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07889388Bionime CorporationRIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study | 2027-03 |
| NCT04270578University Hospital TuebingenGestational Diabetes | 2027-05-01 |
| NCT03313024Charite University, Berlin, GermanyBerlin-Brandenburg Pregnancy Cohort | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Diabetes, Gestational with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot open pre-post clinical trial is to test effects of a wholegrain product in patients with newly diagnosed gestational diabetes. The main question it aims to answer is:
Does the wholegrain product improve glucose tolerance and insulin sensitivity during a 75 g oral glucose tolerance test (OGTT).
Participants will consume product on two consecutive evenings shortly after the first OGTT and will then perform a second OGTT. Researchers will compare the results of the first and second OGTT to see if glucose tolerance improved after consumption of the test product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Only study arm in the study. Participants consume a ready-to-eat wholegrain porridge on two consecutive evenings and repeat OGTT
Other: Ready-to-eat wholegrain porridge
A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
Change in 2 hour glucose in OGTT
Change of the 2 hour glucose value in an oral glucose tolerance test
Time frame: 3-7 working days
Change of the fasting glucose values
Change in in fasting plasma glucose
Time frame: 3-7 working days
Change in 1h glucose in OGTT
Change of the 1h glucose value in an oral glucose tolerance test from the first to the second OGTT
Time frame: 3-7 working days
Number of values changing from diabetic to non-diabetic values per patient
Number of values changing from above the diabetic threshold to below diabetic threshold per patient in the cohort according to World Health Organization (WHO) definitions
Time frame: 3-7 working days
Number of individuals converting from diabetic to non-diabetic OGTT / fasting glucose
Number of individuals converting from diabetic to non-diabetic OGTT / fasting glucose according to WHO criteria
Time frame: 3-7 working days
Change in plasma insulin fasting
Change in plasma insulin fasting between 1st and second OGTT
Time frame: 3-7 working days
Change in plasma insulin 1 hour during OGTT
Change in plasma insulin 1 hour during OGTT between 1st and second OGTT
Time frame: 3-7 working days
Change in plasma insulin 2 hour during OGTT
Change in plasma insulin 2 hour during OGTT between 1st and second OGTT
Time frame: 3-7 working days
Change in homeostasis model assessment (HOMA) Index between 1st and second OGTT
Change in HOMA Index between 1st and second OGTT
Time frame: 3-7 working days
Started May 2023 (actual). Primary completion is estimated for Dec 2023, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Recruitment was not possible.
Recruitment was not possible.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stoffwechselzentrum Rhein - Pfalz